Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Camurus AB ( (SE:CAMX) ) just unveiled an update.
Camurus announced that its product Oczyesa, a once-monthly subcutaneous octreotide, has received marketing authorization from the European Commission for treating acromegaly in adults. This approval marks a significant advancement as Oczyesa offers a convenient self-administration option and has shown superior biochemical control and improved quality of life in clinical trials, positioning Camurus as a leader in innovative treatments for rare diseases.
The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.
More about Camurus AB
Camurus is an international biopharmaceutical company focused on developing long-acting medicines for severe and chronic diseases. Utilizing its proprietary FluidCrystal technology, the company has a diverse R&D pipeline targeting dependence, pain, cancer, and endocrine diseases. Headquartered in Lund, Sweden, Camurus operates in Europe, the US, and Australia, and is listed on Nasdaq Stockholm.
Average Trading Volume: 199,993
Current Market Cap: SEK36.22B
For a thorough assessment of CAMX stock, go to TipRanks’ Stock Analysis page.